Evidence map›Paper›PMID 40397669›Full record

ArticleBiochemistry2025

Structural Insights into Selectively Targeting

Mark E Kowalewski, Sebastian Zagler, Matthew R Redinbo

Abstract read
In one paragraph

Article in Biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mark E KowalewskiDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0001-9455-7333
Sebastian ZaglerDepartment of Chemistry, University of North Carolina, Chapel Hill, North Carolina 27599, United States.ORCID 0009-0002-7337-3652
Matthew R RedinboDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, North Carolina 27599, United States.

Funding

Gut Microbial Enzymes and Human DiseaseR35GM152079 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Matthew R Redinbo · 2024 to 2026
$1.6M
NIGMS NIH HHS R35 GM152079
6 · The paper itself

Abstract

The threat of drug-resistant pathogens continues to rise and underscores the need for new antimicrobial and antifungal strategies. Diverse chemical scaffolds have been shown with high affinity to bind the human heat-shock protein Hsp90. Orthologous proteins are present in microbial pathogens and have been shown to be particularly abundant in these organisms, suggesting they may serve as therapeutic targets. Here, we examine the potency and selectivity of human Hsp90 ligands for their capacity to bind to the nucleotide binding domain of Hsp90 from the pathogenic fungi,

Indexed as

Antifungal AgentsCandida albicansFungal ProteinsHSP90 Heat-Shock ProteinsAdenosine TriphosphateBinding SitesCrystallography, X-RayHumansLigandsModels, MolecularProtein BindingAdenosine TriphosphateAntifungal AgentsFungal ProteinsHSP90 Heat-Shock ProteinsLigands

Identifiers

PMID40397669
PMCPMC12951999

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.